Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.32 |
| ▸ | HRH1 | P35367 | 3/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | BPTF | Q12830 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235448 | 0.82 | SYK (0.42) | SLC6A4SLC6A2SLC6A3ADORA1 | |
| SCHEMBL3265322 | 0.67 | PTGS2 (0.38) | ADORA1BPTF | |
| SCHEMBL3229954 | 0.67 | IDH2 (0.43) | ADORA1TDP1 | |
| Dimethylamine SCHEMBL3266676 | 0.67 | SYK (0.40) | ADORA1ADORA3ADORA2A | |
| SCHEMBL3235563 | 0.66 | IDO1 (0.41) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL3415621 | 0.66 | SYK (0.40) | ADORA1ADORA3 | |
| SCHEMBL3263101 | 0.65 | SYK (0.41) | ADORA1ADORA3ADORA2A | |
| SCHEMBL13456861 | 0.65 | MAPT (0.38) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL3419382 | 0.65 | SYK (0.43) | ADORA1ADORA3ADORA2A | |
| SCHEMBL3261777 | 0.64 | SYK (0.38) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | claimed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | GATAD2B, GATAD2A, RUNX1 | SLC6A4 1680/4885SLC6A2 3132/4885SLC6A3 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.